PrognomiQ

PrognomiQ is a biotechnology company dedicated to the development and commercialization of multi-omics human tests for cancer and other complex diseases. There is a significant unmet need for improved tests to enable earlier detection, treatment, and recurrence monitoring of diseases. PrognomiQ will leverage Seer’s Proteograph, along with genomics and metabolomics technologies, to develop multi-omics products aimed at enhancing human health.